Germany – Pharmaceutical products – Aufhebung der nicht-exklusiven Rabattvereinbarungen nach § 130a Abs. 8 SGB V (Open-House-Modell)

The Open House procedure for the conclusion of non-exclusive rebate contracts pursuant to Section 130a, paragraph 8, SGB V for the medicinal products with the active substances Aflibercept -only in the strength 40mg/ml (ATC Code: S01LA05) and Ranibizumab (ATC Code: S01LA04) is being completely terminated with immediate effect until 31.07.2026. Membership or contract conclusion will then no longer be possible. Already concluded contracts with the contracting parties will be terminated. A new publication will be made in a timely manner.